A comparative study of ß-cell function in newly diagnosed type 2 diabetes patients with fatty liver based on pioglitazone metformin and metformin combined with SGLT-2i and GLP-1RAs respectively

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059806

Enrollment

Unknown

Registered

2022-05-11

Start date

2022-04-29

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Group 1:Metformin + SGLT-2 inhibitors + GLP-1 receptor agonists

Gourp 2:Pioglitazone metformin + SGLT-2 inhibitors + GLP-1 receptor agonists

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-55 years old; 2. BMI is 25-35kg/m2, and waist circumference: male >= 90cm, female >= 85CM; 3. Meet the diagnostic criteria of diabetes in WHO1999; 4. History of fatty liver.

Exclusion criteria

Exclusion criteria: 1. Refusing to sign the informed consent form; 2. Patients with a history of cardiac insufficiency, severe liver function damage, chronic renal insufficiency and other drug contraindications; 3. Those who cannot adhere to the medication during the study, those who need to go out frequently, do not cooperate with the medication, poor compliance, and other possible loss of follow-up; 4. Refusing to retain biological specimens; 5. Patients with severe gastrointestinal diseases; 6. People with bad habits such as alcoholism and/or psychoactive substances, drug abuse or dependence; 7. Have other endocrine diseases or take metabolic drugs that interfere with blood glucose for a long time; 8. Pregnant women; 9. Malignant tumors are not suitable to participate in this study; 10. Those who are allergic to the drug ingredients involved in this study and their allergic constitution; 11. Those who have taken antibiotics or other drugs within 1 week before participating in this study to affect the results of this study; 12. Women with polycystic ovary syndrome; 13. DPP-4 inhibitor users.

Design outcomes

Primary

Measure	Time frame
Blood glucose;Glycosylated hemoglobin;	—

Secondary

Measure	Time frame
Body mass index;Homeostasis model assessment-IR, HOMA-IR;Homeostasis model assessment-ß, HOMA-ß;	—

Countries

China

Contacts

Public ContactJin Jin

The Fifth Affiliated Hospital of Xinjiang Medical University

jinjin@xjmu.edu.cn+86 13319809893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026